OFM
Omega Fund Management Portfolio holdings
AUM
$154M
This Quarter Return
+92.45%
1 Year Return
-32.78%
3 Year Return
+82.35%
5 Year Return
+29.08%
10 Year Return
+90.46%
AUM
$366M
AUM Growth
+$366M
(+51%)
Cap. Flow
-$37.7M
Cap. Flow
% of AUM
-10.32%
Top 10 Holdings %
Top 10 Hldgs %
94.54%
Holding
16
New
–
Increased
4
Reduced
4
Closed
1
Top Buys
| 1 |
Trevi Therapeutics
TRVI
|
$740K |
| 2 |
Replimune Group
REPL
|
$532K |
| 3 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$162K |
| 4 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
$12.2K |
Top Sells
| 1 |
TBIO
Translate Bio, Inc. Common Stock
TBIO
|
$24.3M |
| 2 |
Gossamer Bio
GOSS
|
$12.4M |
| 3 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
$1.27M |
| 4 |
ESSA Pharma
EPIX
|
$1.19M |
| 5 |
Cidara Therapeutics
CDTX
|
$10.7K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Replimune Group
REPL
$422M
| $132M | 36.13% | 5,344,971 +21,516 | +0.4% | +$532K |
|
|
MORF
2
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $80.5M | 22.01% | 2,975,582 +6,000 | +0.2% | +$162K |
|
|
3
Gossamer Bio
GOSS
$562M
| $43.2M | 11.8% | 3,320,608 -955,118 | -22% | -$12.4M |
|
4
Arcutis Biotherapeutics
ARQT
$1.86B
| $25.5M | 6.98% | 844,680 | – | – |
|
5
Immunic
IMUX
$80.9M
| $16.6M | 4.55% | 1,371,494 | – | – |
|
|
PRTK
6
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $13.6M | 3.71% | 2,602,739 +2,329 | +0.1% | +$12.2K |
|
|
7
ESSA Pharma
EPIX
$11.4M
| $9.28M | 2.54% | 1,497,448 -192,400 | -11% | -$1.19M |
|
|
8
Trevi Therapeutics
TRVI
$883M
| $9.05M | 2.48% | 1,375,907 +112,499 | +9% | +$740K |
|
9
Beam Therapeutics
BEAM
$1.66B
| $8.48M | 2.32% | 302,821 | – | – |
|
|
10
Cidara Therapeutics
CDTX
$1.66B
| $7.4M | 2.02% | 2,005,249 -2,901 | -0.1% | -$10.7K |
|
|
OBSV
11
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $5.89M | 1.61% | 999,364 | – | – |
|
12
FibroGen
FGEN
$47.8M
| $5.3M | 1.45% | 130,646 | – | – |
|
|
JNCE
13
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $3.66M | 1% | 529,965 | – | – |
|
|
PRVL
14
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $2.79M | 0.76% | 187,538 -85,269 | -31% | -$1.27M |
|
|
PVLA
15
Palvella Therapeutics, Inc. Common Stock
PVLA
$599M
| $2.33M | 0.64% | 750,741 | – | – |
|
|
TBIO
16
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| – | – | -2,437,603 | Closed | -$24.3M |
|